Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy

Abstract

BackgroundOral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both surgery and radiotherapy have significant functional side effects, notably impaired ability to eat, drink and talk. The development of new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy treatments may potentially bring about increases in both survival and quality of life for this group of patients. ObjectivesTo determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal cancer results in improved survival, disease free survival, progression free survival, locoregional control and reduced recurrence of disease. To determine which regimen and time of administration (induction, concomitant or adjuvant) is associated with better outcomes. Search methodsElectronic searches of the Cochrane Oral Health Group's Trials Register, CENTRAL, MEDLINE, EMBASE, AMED were undertaken on 1st December 2010. Reference lists of recent reviews and included studies were also searched to identify further trials. Selection criteriaRandomised controlled trials where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and which compared the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more chemotherapy regimens or modes of administration, were included. 1 Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)

Advancing nanotechnology for neoantigen-based cancer theranostics

“…30 Side effects such as systemic chemotherapy and multidrug resistance are the most frequently encountered issues in cancer chemotherapy. 170 It remains a huge challenge to improve therapeutic efficacy as well as minimize the adverse effect. Inspired by this, Chen et al developed cancer cell membranes (CM)@cobalt-ferrocene metal-organic framework (Co-Fc)@ hydroxychloroquine (HCQ) (CM@Co-Fc@HCQ) for effective ablation of OSCC (Fig.…”

Review of patient‐reported outcomes (PROs) and non‐PROs in randomized controlled trials addressing head/neck cancers

“…The following research questions were used to guide the conduct of the present study: (1) What kinds of non-PROs and PROs are reported in RCTs involving the treatment of head and neck neoplasms? (2) Are there any temporal trends in the reporting of PROs in RCTs involving the treatment of head and neck neoplasms?…”

“…In contrast, relying only on outcomes from the perspective of the researcher provides a limited view of the potential impact of therapies. For example, Parmar et al 1 is a systematic review of compiled evidence on the effect of chemotherapy for treating oral and oropharyngeal cancer. However, it only reports endpoints for survival and locoregional control.…”

GSR Mediates Cisplatin Resistance in Oral Cancer by Protecting Mitochondria

“…Author details 1 4 Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, 430079, China. 5 Authors contributing equally to this work. 6 Lead contact *Corresponding Author: Hongyu Yang, E-mail: hyyang192@hotmail.com; Gang Chen, E-mail: geraldchan@whu.edu.cn…”

“…However, some tumors are highly aggressive and resistant to chemotherapy and are often associated with a poor prognosis [4]. Despite the wide use of cisplatin-based chemotherapy, the overall cure rate of patients with R/M OSCC remains very low, with an estimated 5-year survival rate of < 50% [5].…”